![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: AXL |
Gene summary for AXL |
![]() |
Gene information | Species | Human | Gene symbol | AXL | Gene ID | 558 |
Gene name | AXL receptor tyrosine kinase | |
Gene Alias | ARK | |
Cytomap | 19q13.2 | |
Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | M0R0W6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
558 | AXL | LZE6T | Human | Esophagus | ESCC | 4.24e-02 | 2.95e-01 | 0.0845 |
558 | AXL | P2T-E | Human | Esophagus | ESCC | 3.40e-13 | 9.01e-02 | 0.1177 |
558 | AXL | P8T-E | Human | Esophagus | ESCC | 1.16e-06 | 1.49e-01 | 0.0889 |
558 | AXL | P11T-E | Human | Esophagus | ESCC | 2.83e-05 | 3.59e-01 | 0.1426 |
558 | AXL | P12T-E | Human | Esophagus | ESCC | 2.46e-10 | 1.62e-01 | 0.1122 |
558 | AXL | P17T-E | Human | Esophagus | ESCC | 9.69e-03 | 2.99e-01 | 0.1278 |
558 | AXL | P21T-E | Human | Esophagus | ESCC | 5.53e-08 | 1.06e-01 | 0.1617 |
558 | AXL | P24T-E | Human | Esophagus | ESCC | 6.45e-05 | 1.35e-01 | 0.1287 |
558 | AXL | P26T-E | Human | Esophagus | ESCC | 5.47e-11 | 1.96e-01 | 0.1276 |
558 | AXL | P31T-E | Human | Esophagus | ESCC | 5.43e-04 | 4.54e-02 | 0.1251 |
558 | AXL | P32T-E | Human | Esophagus | ESCC | 4.84e-12 | 2.87e-01 | 0.1666 |
558 | AXL | P37T-E | Human | Esophagus | ESCC | 9.46e-17 | 3.86e-01 | 0.1371 |
558 | AXL | P44T-E | Human | Esophagus | ESCC | 1.70e-10 | 3.28e-01 | 0.1096 |
558 | AXL | P61T-E | Human | Esophagus | ESCC | 2.13e-08 | 2.14e-01 | 0.099 |
558 | AXL | P74T-E | Human | Esophagus | ESCC | 9.96e-04 | 1.40e-01 | 0.1479 |
558 | AXL | P76T-E | Human | Esophagus | ESCC | 7.70e-10 | 2.32e-01 | 0.1207 |
558 | AXL | P79T-E | Human | Esophagus | ESCC | 8.26e-10 | 1.98e-01 | 0.1154 |
558 | AXL | P82T-E | Human | Esophagus | ESCC | 1.70e-03 | 5.62e-01 | 0.1072 |
558 | AXL | P83T-E | Human | Esophagus | ESCC | 5.44e-04 | 2.12e-01 | 0.1738 |
558 | AXL | P130T-E | Human | Esophagus | ESCC | 8.78e-22 | 5.29e-01 | 0.1676 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0016032111 | Esophagus | ESCC | viral process | 301/8552 | 415/18723 | 3.34e-29 | 1.32e-26 | 301 |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:0019058111 | Esophagus | ESCC | viral life cycle | 226/8552 | 317/18723 | 1.17e-20 | 1.76e-18 | 226 |
GO:0062197111 | Esophagus | ESCC | cellular response to chemical stress | 234/8552 | 337/18723 | 5.37e-19 | 5.97e-17 | 234 |
GO:0034599111 | Esophagus | ESCC | cellular response to oxidative stress | 197/8552 | 288/18723 | 3.76e-15 | 2.15e-13 | 197 |
GO:0071496111 | Esophagus | ESCC | cellular response to external stimulus | 215/8552 | 320/18723 | 4.29e-15 | 2.43e-13 | 215 |
GO:0031668111 | Esophagus | ESCC | cellular response to extracellular stimulus | 168/8552 | 246/18723 | 4.93e-13 | 2.23e-11 | 168 |
GO:0050792111 | Esophagus | ESCC | regulation of viral process | 119/8552 | 164/18723 | 2.19e-12 | 9.03e-11 | 119 |
GO:0000302111 | Esophagus | ESCC | response to reactive oxygen species | 150/8552 | 222/18723 | 3.06e-11 | 1.02e-09 | 150 |
GO:1903900111 | Esophagus | ESCC | regulation of viral life cycle | 106/8552 | 148/18723 | 1.26e-10 | 3.72e-09 | 106 |
GO:0044403111 | Esophagus | ESCC | biological process involved in symbiotic interaction | 186/8552 | 290/18723 | 1.43e-10 | 4.16e-09 | 186 |
GO:0051701111 | Esophagus | ESCC | biological process involved in interaction with host | 135/8552 | 203/18723 | 1.49e-09 | 3.49e-08 | 135 |
GO:0042542111 | Esophagus | ESCC | response to hydrogen peroxide | 102/8552 | 146/18723 | 2.64e-09 | 5.81e-08 | 102 |
GO:003158919 | Esophagus | ESCC | cell-substrate adhesion | 221/8552 | 363/18723 | 3.06e-09 | 6.62e-08 | 221 |
GO:0052126111 | Esophagus | ESCC | movement in host environment | 117/8552 | 175/18723 | 1.14e-08 | 2.26e-07 | 117 |
GO:0048524110 | Esophagus | ESCC | positive regulation of viral process | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
GO:0070997111 | Esophagus | ESCC | neuron death | 216/8552 | 361/18723 | 3.49e-08 | 6.45e-07 | 216 |
GO:003010018 | Esophagus | ESCC | regulation of endocytosis | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:003461420 | Esophagus | ESCC | cellular response to reactive oxygen species | 103/8552 | 155/18723 | 1.34e-07 | 2.17e-06 | 103 |
GO:0002262111 | Esophagus | ESCC | myeloid cell homeostasis | 104/8552 | 157/18723 | 1.49e-07 | 2.36e-06 | 104 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0152110 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa0152115 | Esophagus | ESCC | EGFR tyrosine kinase inhibitor resistance | 55/4205 | 79/8465 | 2.44e-04 | 8.78e-04 | 4.50e-04 | 55 |
hsa015219 | Oral cavity | OSCC | EGFR tyrosine kinase inhibitor resistance | 54/3704 | 79/8465 | 8.11e-06 | 3.72e-05 | 1.89e-05 | 54 |
hsa0152114 | Oral cavity | OSCC | EGFR tyrosine kinase inhibitor resistance | 54/3704 | 79/8465 | 8.11e-06 | 3.72e-05 | 1.89e-05 | 54 |
hsa0152142 | Oral cavity | NEOLP | EGFR tyrosine kinase inhibitor resistance | 20/1112 | 79/8465 | 2.47e-03 | 1.03e-02 | 6.49e-03 | 20 |
hsa0152152 | Oral cavity | NEOLP | EGFR tyrosine kinase inhibitor resistance | 20/1112 | 79/8465 | 2.47e-03 | 1.03e-02 | 6.49e-03 | 20 |
hsa015218 | Prostate | BPH | EGFR tyrosine kinase inhibitor resistance | 30/1718 | 79/8465 | 2.10e-04 | 1.13e-03 | 6.98e-04 | 30 |
hsa0152113 | Prostate | BPH | EGFR tyrosine kinase inhibitor resistance | 30/1718 | 79/8465 | 2.10e-04 | 1.13e-03 | 6.98e-04 | 30 |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
GAS6 | AXL | GAS6_AXL | GAS | Breast | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | Breast | ADJ |
GAS6 | AXL | GAS6_AXL | GAS | Breast | DCIS |
PROS1 | AXL | PROS1_AXL | PROS | Breast | DCIS |
GAS6 | AXL | GAS6_AXL | GAS | Breast | Healthy |
PROS1 | AXL | PROS1_AXL | PROS | Breast | Healthy |
GAS6 | AXL | GAS6_AXL | GAS | Breast | IDC |
GAS6 | AXL | GAS6_AXL | GAS | Breast | Precancer |
GAS6 | AXL | GAS6_AXL | GAS | Cervix | ADJ |
PROS1 | AXL | PROS1_AXL | PROS | Cervix | ADJ |
GAS6 | AXL | GAS6_AXL | GAS | Cervix | CC |
PROS1 | AXL | PROS1_AXL | PROS | Cervix | CC |
GAS6 | AXL | GAS6_AXL | GAS | Cervix | Healthy |
PROS1 | AXL | PROS1_AXL | PROS | Cervix | Healthy |
GAS6 | AXL | GAS6_AXL | GAS | Cervix | Precancer |
GAS6 | AXL | GAS6_AXL | GAS | CRC | AD |
GAS6 | AXL | GAS6_AXL | GAS | CRC | ADJ |
GAS6 | AXL | GAS6_AXL | GAS | CRC | CRC |
GAS6 | AXL | GAS6_AXL | GAS | CRC | MSI-H |
GAS6 | AXL | GAS6_AXL | GAS | CRC | MSS |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AXL | insertion | Frame_Shift_Ins | rs778012871 | c.867_868insC | p.His292ProfsTer47 | p.H292Pfs*47 | P30530 | protein_coding | TCGA-B7-A5TI-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | eloxatin | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | DASATINIB | DASATINIB | ||
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | PF-562271 | PF-00562271 | ||
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 363894214 | SITRAVATINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 404859021 | ||
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | HESPERADIN | HESPERADIN | 19035792 |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 363894135 | MERESTINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | XL999 | |||
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | Gilteritinib | GILTERITINIB | ||
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | inhibitor | 252827520 | DUBERMATINIB | |
558 | AXL | CLINICALLY ACTIONABLE, DRUGGABLE GENOME, ENZYME, KINASE, TYROSINE KINASE, CELL SURFACE | BI-505 | BI-505 |
Page: 1 2 3 4 5 |